112 related articles for article (PubMed ID: 1566442)
1. Activation of endothelial cells in hyperacute xenograft rejection.
Geller RL; Bach FH; Vercellotti GM; Nistler RS; Bolman RM; Fischel RJ; Leventhal J; Platt JL
Transplant Proc; 1992 Apr; 24(2):592. PubMed ID: 1566442
[No Abstract] [Full Text] [Related]
2. Prevention of hyperacute xenograft rejection by intravenous immunoglobulin in the pig-to-human combination.
Gautreau C; Cardoso J; Woimant G; Zhao Z; Chereau C; Cherruau B; Vandeginste N; Devillier P; Houssin D
Transplant Proc; 1994 Jun; 26(3):1281. PubMed ID: 8029908
[No Abstract] [Full Text] [Related]
3. Potentiation of C1 inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection.
Dalmasso AP; Platt JL
Transplant Proc; 1994 Jun; 26(3):1246-7. PubMed ID: 8029898
[No Abstract] [Full Text] [Related]
4. Complement mediates attenuation of endothelium-dependent relaxations in canine coronary arteries after porcine serum exposure: a mechanism for vascular thrombosis in xenograft hyperacute rejection.
Cable DG; Hisamochi K; Schaff HV
Circulation; 1997 Nov; 96(9 Suppl):II-58-63; discussion II-63-4. PubMed ID: 9386076
[TBL] [Abstract][Full Text] [Related]
5. Discordant complement systems as a factor in hyperacute xenograft rejection.
Yang Q; Wang YY; Bollinger RR; De Buysscher EV
Transplant Proc; 1992 Apr; 24(2):481-2. PubMed ID: 1566396
[No Abstract] [Full Text] [Related]
6. The role of cell-surface glycoproteins in the activation of endothelial cells by antibody and complement.
Lindman BJ; Noreen HJ; Geller RL; Dalmasso AP; Bach FH; Platt JL
Transplant Proc; 1992 Apr; 24(2):586-7. PubMed ID: 1566439
[No Abstract] [Full Text] [Related]
7. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation.
Kroshus TJ; Rollins SA; Dalmasso AP; Elliott EA; Matis LA; Squinto SP; Bolman RM
Transplantation; 1995 Dec; 60(11):1194-202. PubMed ID: 8525509
[TBL] [Abstract][Full Text] [Related]
8. A synthetic dextran derivative inhibits complement activation and complement-mediated cytotoxicity in an in vitro model of hyperacute xenograft rejection.
Thomas H; Maillet F; Letourneur D; Jozefonvicz J; Kazatchkine MD; Fischer E
Transplant Proc; 1996 Apr; 28(2):593-4. PubMed ID: 8623290
[No Abstract] [Full Text] [Related]
9. Genetic engineering of endothelial cells to ameliorate xenograft rejection.
Bach FH; Robson SC; Wrighton CJ; Stuhlmeier K; Ferran C; Winkler H
Clin Transplant; 1996 Feb; 10(1 Pt 2):124-7. PubMed ID: 8680048
[TBL] [Abstract][Full Text] [Related]
10. Hyperacute rejection of renal discordant xenograft (pig-to-rabbit): model assessment and rejection mechanisms.
Marino IR; Ferla G; Celli S; Stieber A; Muttillo I; Maggiano N; Mazzaferro V; Perrelli L; Musiani P
Transplant Proc; 1990 Jun; 22(3):1071-6. PubMed ID: 2190372
[No Abstract] [Full Text] [Related]
11. Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood.
Banz Y; Cung T; Korchagina EY; Bovin NV; Haeberli A; Rieben R
Xenotransplantation; 2005 Nov; 12(6):434-43. PubMed ID: 16202066
[TBL] [Abstract][Full Text] [Related]
12. [Xenotransplantation: physiopathology of hyperacute and differentiated rejection, and therapeutic perspectives].
Malassagne B; Calmus Y; Houssin D; Weill B
Pathol Biol (Paris); 2000 May; 48(4):377-82. PubMed ID: 10868402
[TBL] [Abstract][Full Text] [Related]
13. Xenograft rejection--molecular mechanisms and therapeutic implications.
Magee JC; Platt JL
Ther Immunol; 1994 Jan; 1(1):45-58. PubMed ID: 7584479
[TBL] [Abstract][Full Text] [Related]
14. Prevention of hyperacute xenograft rejection by intravenous immunoglobulin.
Magee JC; Collins BH; Harland RC; Bollinger RR; Frank MM; Platt JL
Transplant Proc; 1995 Feb; 27(1):271. PubMed ID: 7878999
[No Abstract] [Full Text] [Related]
15. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells.
Laumonier T; Walpen AJ; Maurus CF; Mohacsi PJ; Matozan KM; Korchagina EY; Bovin NV; Vanhove B; Seebach JD; Rieben R
Transplantation; 2003 Sep; 76(5):838-43. PubMed ID: 14501864
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis and pathology of delayed xenograft rejection in pig-to-rhesus monkey cardiac transplantation.
Chen D; Cao R; Guo H; Chen G; Wang X; Shen S; Chen S
Transplant Proc; 2004 Oct; 36(8):2480-2. PubMed ID: 15561288
[TBL] [Abstract][Full Text] [Related]
17. Removal of IgM anti-endothelial antibodies results in prolonged cardiac xenograft survival.
Fischel RJ; Bolman RM; Platt JL; Najarian JS; Bach FH; Matas AJ
Transplant Proc; 1990 Jun; 22(3):1077-8. PubMed ID: 2190373
[No Abstract] [Full Text] [Related]
18. Hyperacute xenograft rejection in the swine-to-human donor-recipient combination. In vitro analysis of complement activation.
Zhao Z; Termignon JL; Cardoso J; Chéreau C; Gautreau C; Calmus Y; Houssin D; Weill B
Transplantation; 1994 Jan; 57(2):245-9. PubMed ID: 8310516
[TBL] [Abstract][Full Text] [Related]
19. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection.
Cary N; Moody J; Yannoutsos N; Wallwork J; White D
Transplant Proc; 1993 Feb; 25(1 Pt 1):400-1. PubMed ID: 7679815
[No Abstract] [Full Text] [Related]
20. Xenograft rejection: IgG1, complement and NK cells team up to activate and destroy the endothelium.
Rieben R; Seebach JD
Trends Immunol; 2005 Jan; 26(1):2-5. PubMed ID: 15629401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
